People: Cepheid (CPHD.O)
CPHD.O on Nasdaq
14.99USD
9 Feb 2010
14.99USD
9 Feb 2010
Price Change (% chg)
$0.28 (+1.90%)
$0.28 (+1.90%)
Prev Close
$14.99
$14.99
Open
--
--
Day's High
$15.14
$15.14
Day's Low
$14.69
$14.69
Volume
273,718
273,718
Avg. Vol
495,898
495,898
52-wk High
$16.47
$16.47
52-wk Low
$4.93
$4.93
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
| Gutshall, Thomas | 71 | 2002 | Chairman of the Board |
| Bishop, John | 64 | 2002 | Chief Executive Officer, Director |
| Miller, Andrew | 48 | 2008 | Chief Financial Officer, Senior Vice President |
| Reyes, Humberto | 63 | 2008 | Chief Operating Officer, Executive Vice President |
| Persing, David | 53 | 2005 | Executive Vice President, Chief Medical and Technology Officer, Director |
| Arnold, Nicolaas | 2009 | Executive Vice President - Worldwide Commercial Operations | |
| Smith, Joseph | 64 | 2004 | Senior Vice President, General Counsel and Secretary |
| King, Laurie | 55 | 2008 | Senior Vice President - Human Resources |
| Koska, Robert | 51 | 2007 | Senior Vice President - Worldwide Commercial Operations |
| Enns, Russell | 60 | 2003 | Senior Vice President - Regulatory and Clinical Affairs, Quality System and Reimbursement |
| Dailey, Peter | 54 | 2008 | Senior Vice President - Research and Development |
| Kepner, Cristina | 62 | 1998 | Director |
| Morton, Dean | 76 | 1997 | Director |
| Renton, Hollings | 62 | 2000 | Director |
| Easton, Robert | 64 | 2002 | Director |
| Mroz, Mitchell | 64 | 2004 | Director |
| Brown, Thomas | 60 | 2006 | Director |
Biographies
| Name | Description |
|---|---|
| Gutshall, Thomas | Thomas L. Gutshall is a co-founder of Cepheid and has served as Chairman of the Board since August 1996. From August 1996 until April 2002, he also served as Chief Executive Officer of the Company. From January 1995 to August 1996, he was President and Chief Operating Officer of CV Therapeutics. From 1989 to 1994, he was Executive Vice President at Syntex Corporation and a member of the Pharmaceutical Executive Committee. His responsibilities while at Syntex included managing Syva Company, Syntex Agribusiness, Pharmaceutical and Chemical Operations and Services, Syntex Pharmaceutical Intl. Ltd. and Environmental Health and Safety. Mr. Gutshall currently serves as a director of CV Therapeutics and Satoris Corporation and is a Board member of the Pacific Medical Research Foundation. |
| Bishop, John | John L. Bishop has joined Cepheid as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories, from 1993 to 2002 and as Chief Executive Officer from 1996 to 2002. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop currently serves as a member of the Board of the Biotechnology Industry Organization (BIO) and the BIO Health Section Governing Board. Mr. Bishop is also a director of Conceptus, Inc. |
| Miller, Andrew | Andrew D. Miller has been Senior Vice President, Chief Financial Officer of Cepheid, since April 2008. Prior to joining Cepheid, Mr. Miller was Vice President and Chief Accounting Officer for Autodesk, an enterprise software company, from 2003 to April 2008. Before joining Autodesk, from 2000 to 2003, Mr. Miller was Senior Vice President and Chief Financial Officer for MarketFirst Software, Inc., a leading provider of enterprise marketing automation software. Prior to MarketFirst, Mr. Miller served as Vice President of Worldwide Finance for Cadence Design Systems, Vice President of Finance and Corporate Controller for Adaptive Broadband Corporation, and senior financial roles for Silicon Graphics, Inc. Mr. Miller graduated Summa Cum Laude from Santa Clara University with a BS degree in Commerce and is a CPA. |
| Reyes, Humberto | Humberto Reyes has been Executive Vice President, Chief Operating Officer of Cepheid. Mr. Reyes joined the company as Senior Vice President of Operations in November 2004 and became the company's Executive Vice President of Operations in November 2006. Prior to joining Cepheid, Mr. Reyes was an Operations Consultant with Brownsboro Group, LLC. from 2003 to 2004. Prior to joining Brownsboro, Mr. Reyes was a Senior Operations Consultant for EXPERTech Associates, consulting in medical devices and biotech industries from 2001 to 2003. Prior to that, he was Head of Operations for OXIS Health Products Inc., which developed, manufactured and marketed products for oxidative research and wellness programs from 1997 to 2001. He is an experienced operations executive with more than 25 years of progressive management experience in the diagnostic and related industries. Mr. Reyes’ work experience also includes Vice President, Operations, Dade Diagnostics at Baxter; Vice President/General Manager, Chromatography Division, Varian and Associates; and Sr. Vice President, Operations, Microgenics Corporation. |
| Persing, David | David H. Persing has joined Cepheid as a director in May 2004, and then became Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to July 2005, Dr. Persing was Senior Vice President and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until their acquisition by GlaxoSmithkline. From 1990 to 1999 he was a member of the Clinical and Research Faculty of the Mayo Clinic in Rochester, Minnesota where he researched programs on hepatitis viruses and tick-borne infections. In 1992 he founded and directed the Molecular Microbiology Laboratory at Mayo Clinic. He has authored over 240 peer-reviewed articles and served as Editor in Chief for three textbooks on molecular diagnostics, the most recent of which was published by ASM press in December 2004. Dr. Persing currently serves as a director of Monogram Biosciences, Inc. |
| Arnold, Nicolaas | Mr. Nicolaas ('Nico') Arnold has been appointed as Executive Vice President - Worldwide Commercial Operations of Cepheid effective October 14, 2009. Mr. Arnold joins Cepheid from Siemens and, previously, from Diagnostic Products Corporation which was acquired by Siemens in 2006. Building on his academic and early research experience in clinical laboratories, Mr. Arnold brings more than 25 years of global sales and marketing experience in diagnostics to Cepheid. Most recently, Mr. Arnold was Regional Vice President for Siemens Healthcare Diagnostics in Northwest Europe with responsibility for molecular diagnostics, central lab and point of care sales. Previous roles included Managing Director of European sales for Siemens Medical Diagnostics, with responsibility for more than $1 billion in sales annually, and Vice President of Global Marketing and US Sales for Diagnostic Product Corporation, with total revenues in excess of $500 million. |
| Smith, Joseph | Joseph H. Smith has been Senior Vice President, General Counsel and Secretary of Cepheid. Mr. Smith joined the company in June 2003 and now serves as Senior Vice President and General Counsel. He has been Secretary of the Corporation since March 2004. From 1989 to 2002, Mr. Smith was Vice President of Intellectual Property at ABI (now Life Technologies Corporation) and its predecessors, a biotechnology research equipment company, and from 2002 to 2003 was its Senior Vice President for Business Development. Prior to ABI, Mr. Smith was a partner in the law firm of Wiseman, Jones, and Smith; and prior to that he was also a member of the Technical Legal Department of Hewlett-Packard. |
| King, Laurie | Laurie King has been Senior Vice President - Human Resources of Cepheid. Ms. King was promoted to Senior Vice President, Human Resources in April 2008, having joined the company in January 2003 as Director, Human Resources and promoted to Vice President, Human Resources in 2004. Prior to joining Cepheid Ms. King held the positions of Vice President, Human Resources for Incyte, a genomic technology company, Risk Management Solutions, a risk quantification company and the American Electronics Association, a trade association for the technology industry. Ms. King has more than 25 years experience in Human Resources, is a member of the Bay Area Human Resources Executive Council, and served as West Coast co-chair of the 2008 BIO HR Conference. |
| Koska, Robert | Robert J. Koska has been Senior Vice President, Worldwide Commercial Operations of Cepheid. Mr. Koska joined the company in February 2005 and since September 2007 has served as the company's Senior Vice President, Worldwide Commercial Operations. Prior to joining Cepheid, Mr. Koska held various positions with Vysis, Inc. and subsequently Abbott Laboratories since 1996. Mr. Koska’s work experience includes Divisional Vice President, Vysis U.S. and Canadian Sales at Abbott Molecular Diagnostics, and Senior Vice President Worldwide Sales & Marketing, Vysis prior to the Abbott acquisition. Mr. Koska further previously held progressive positions of increased responsibility in sales and marketing at DIFCO Laboratories, Inc., Bristol Myers Genetic Systems Corporation, and Johnson and Johnson’s Ortho Diagnostic Systems, Inc. Mr. Koska has an MBA, Marketing Emphasis, from the University of Michigan, Ann Arbor, MI, and a BS degree in Medical Technology from Wayne State University, Detroit, MI. |
| Enns, Russell | Russel K. Enns, Ph.D. has been Senior Vice President - Regulatory and Clinical Affairs, Quality System and Reimbursement of Cepheid, since June 2003. Prior to joining Cepheid, Dr. Enns was Divisional Vice President for Regulatory and Clinical Affairs, Quality Systems, and Medical Reimbursement at Vysis, Inc., a genomic disease management company that was acquired by Abbott Laboratories, from 1995 to 2003. Before joining Vysis, he was Vice President, Technical Affairs of MicroProbe Corporation, a biotechnology company, from 1992 to 1995. Before joining MicroProbe Corporation, he was Director of Product Development, Clinical Programs and Technical Affairs at GenProbe, Inc., a biotechnology diagnostic company, from 1984 to 1992. From 1979 to 1984, Dr. Enns was the Director of Cell Biology at Alpha Therapeutics Corporation, and from 1975 to 1979 he was a Senior Biochemist at Monsanto Corporation. He received his Ph.D. in Biochemistry from University of California at Davis in 1976. Dr. Enns is a charter member and past chair of the Clinical and Laboratory Standards Institute (“CLSI”) Area Committee on Molecular Methods, and he is currently a member of the CLSI Board of Directors. |
| Dailey, Peter | Peter J. Dailey, Ph.D. has been Senior Vice President, Research and Development of Cepheid. Dr. Dailey joined the company as Vice President, Research and Development in June 2006 and now serves as the comapny's Senior Vice President, Research and Development. Prior to joining Cepheid, Dr. Dailey was the Senior Director of the Department of Infectious Disease in Discovery Research at Roche Molecular Systems, Inc., from 2002 to 2006. He is a microbiologist and virologist by training and has worked in the field of diagnostic microbiology for the last 25 years. Dr. Dailey worked as a Public Health Microbiologist at the California State Dept. of Health’s Viral & Rickettsial Disease Laboratory in Berkeley, California in the 1980s on the development of diagnostic assays for HIV and HTLV. He also worked many years as a Clinical Laboratory microbiologist in medical centers, hospitals, and reference laboratories. Beginning in 1990, he was employed at Chiron Diagnostics (now Bayer Diagnostics) working on the research, development, and application of nucleic acid probe assays, in particular viral load assays for HCV, HIV, and SIV. He has served as a subcommittee member on the National Committee for Clinical Laboratory Standards committee revising Guidelines for Molecular Diagnostic Methods for Infectious Diseases and has authored or co-authored more than 35 peer-reviewed papers as well as several book chapters and reviews on infectious disease nucleic acid diagnostic assays. |
| Kepner, Cristina | Cristina H. Kepner has joined Cepheid as a director in May 1998. She was with Invemed from 1978 to 2000, where she served in a variety of capacities. Prior to retiring from Invemed in December 2000, Ms. Kepner served as Executive Vice President and Corporate Finance Director. Ms. Kepner also served as a director of Invemed until December 2000. Ms. Kepner currently serves as a director of Monogram Biosciences, Inc. |
| Morton, Dean | Dean O. Morton has joined Cepheid as a director in July 1997. Mr. Morton retired in 1992 as Executive Vice President, Chief Operating Officer and a director of Hewlett-Packard Company, where he started in 1960. Mr. Morton currently serves on the Board of Monterey Bay Aquarium Research Institute and Center for Excellence in Non-Profits. |
| Renton, Hollings | Hollings C. Renton has joined Cepheid as a director in March 2000. Mr. Renton retired from Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, in March 2008, where he had served as a director beginning in April 1992, President and Chief Executive Officer beginning in March 1993 and Chairman of the Board beginning in June 2003. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991 and as Chief Operating Officer from 1987 to 1990. Mr. Renton also serves as a member of the Boards of Directors of Rigel Pharmaceuticals and Special Olympics of Northern California. |
| Easton, Robert | Robert J. Easton has joined Cepheid as a director in 2002. Mr. Easton is founder and Chairman of Scisive Consulting LP, a strategic consulting firm specializing in evaluation and planning for pharmaceutical and medical device companies. From 2000 to 2007, he was co-founder and Chairman of Easton Associates, LLC, and before that, from 1996 to 2000, he was a Managing Director of IBM Healthcare Consulting. In addition to his consulting experience, Mr. Easton spent 12 years with Union Carbide and Union Carbide Europe in a variety of functional management roles. He currently serves as a director Apex Bioventures, which he co-founded. |
| Mroz, Mitchell | Mitchell D. Mroz has joined Cepheid as a director in May 2004. Mr. Mroz currently serves as a member of the Board of the Northrop Grumman Federal Credit Union and is retired from Northrop Grumman Corporation. Since joining Northrup Grumman in 1978, he served in various capacities, including the positions of Vice President and Chief Financial Officer for Grumman Corporation and Vice President and General Manager of the Automation and Information Systems Division of Northrop Grumman, Corporate Vice President Internal Audit and Audit Manager. Before joining Northrop Grumman, he was an Auditor for the U.S. Air Force Audit Agency and the U.S. General Accounting Office. He also serves on the Board of Directors of Village Christian Schools in Sun Valley, California, and is the Chairman of the Board of the Village Christian Schools Foundation. |
| Brown, Thomas | Thomas D. Brown has joined Cepheid as a director in February 2006. Mr. Brown joined Abbott Laboratories in 1974 as a sales representative in the company’s Diagnostics Division (ADD). From 1977 until his retirement in 2002, he held numerous sales, marketing and general management positions within ADD. From February 1998 until his retirement at Abbott Laboratories in July 2002, he held the position of Senior Vice President, President Diagnostic Division. In 1993 he was elected Corporate Vice President Worldwide Diagnostic Commercial Operations. In 1992 he was named Divisional Vice President, Commercial Operations. In 1987 he was named Divisional Vice President and General Manager, Western Hemisphere Commercial Operations. Mr. Brown serves on the Board of Directors for Quidel Corporation and Stericycle. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
| Gutshall, Thomas | 142,198 |
| Bishop, John | 1,459,010 |
| Miller, Andrew | 744,463 |
| Reyes, Humberto | 989,096 |
| Persing, David | 1,027,120 |
| Arnold, Nicolaas | -- |
| Smith, Joseph | 623,359 |
| King, Laurie | -- |
| Koska, Robert | 1,030,340 |
| Enns, Russell | 208,661 |
| Dailey, Peter | -- |
| Kepner, Cristina | -- |
| Morton, Dean | -- |
| Renton, Hollings | -- |
| Easton, Robert | -- |
| Mroz, Mitchell | -- |
| Brown, Thomas | -- |
As Of 30 Dec 2008
Options Compensation
| Name | Options | Value |
|---|---|---|
| Gutshall, Thomas | 250,000 | 1,396,250 |
| Bishop, John | 1,443,113 | 15,777,204 |
| Miller, Andrew | 0 | 0 |
| Reyes, Humberto | 205,000 | 523,041 |
| Persing, David | 358,250 | 638,876 |
| Arnold, Nicolaas | 0 | 0 |
| Smith, Joseph | 310,000 | 1,141,451 |
| King, Laurie | 0 | 0 |
| Koska, Robert | 51,367 | 989,720 |
| Enns, Russell | 170,000 | 896,301 |
| Dailey, Peter | 0 | 0 |
| Kepner, Cristina | 0 | 0 |
| Morton, Dean | 0 | 0 |
| Renton, Hollings | 0 | 0 |
| Easton, Robert | 0 | 0 |
| Mroz, Mitchell | 0 | 0 |
| Brown, Thomas | 0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
| GUTSHALL THOMAS L | 1,000 | $14.91 |
| DAILEY PETER J | 2,500 | $14.95 |
| DAILEY PETER J | 22,161 | $14.50 |
| DAILEY PETER J | 20,000 | $9.02 |
| GUTSHALL THOMAS L | 1,000 | $12.72 |
| GUTSHALL THOMAS L | 9,000 | $0.00 |
| GUTSHALL THOMAS L | 1,000 | $13.20 |
| GUTSHALL THOMAS L | 9,000 | $0.00 |
| GUTSHALL THOMAS L | 1,000 | $13.87 |
| PERSING DAVID H | 60,000 | $7.38 |
| GUTSHALL THOMAS L | 1,000 | $13.73 |
| GUTSHALL THOMAS L | 1,000 | $12.39 |
| GUTSHALL THOMAS L | 3,000 | $0.00 |
| GUTSHALL THOMAS L | 3,000 | $0.00 |
| KOSKA ROBERT J | 2,332 | $12.45 |
| KOSKA ROBERT J | 1,418 | $12.47 |
| GUTSHALL THOMAS L | 1,000 | $10.86 |
| GUTSHALL THOMAS L | 1,000 | $9.23 |
| GUTSHALL THOMAS L | 1,000 | $10.20 |
| GUTSHALL THOMAS L | 3,000 | $0.00 |
| GUTSHALL THOMAS L | 3,000 | $0.00 |
| KEPNER CRISTINA H | 25,000 | $10.05 |
| GUTSHALL THOMAS L | 37,025 | $2.32 |
| GUTSHALL THOMAS L | 50,000 | $1.50 |
| MORTON DEAN O | 5,000 | $7.11 |
© Copyright 2010 Thomson Reuters
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
